Version Française

Develop quality in the health,
social and medico-social field

Search

impression
Transparency_Committee_Opinion

LOJUXTA

Active substance (DCI)
  • lomitapide
-

Reason for request
Inclusion

Date 08 January 2014

Indications concerned
-

-


Actual benefit

Important

The actual benefit provided by LOJUXTA in combination with other lipid lowering medicines is substantial in adult patients with homozygous familial hypercholesterolaemia (HoFH) uncontrolled by these lipid-lowering treatments used at maximum doses, whether or not combined with apheresis.


Improvement in actual benefit

IV (mineur)

The addition of LOJUXTA to an optimal lipid-lowering therapy, used at maximum doses, whether or not combined with apheres is, in adult patients with uncontrolled homozygous familial hypercholesterolaemia (HoFH), provides a minor improvement in actual benefit (IABIV).


Documents

English version

ATC Code
  • C10AX12
Laboratory / Manufacturer
AEGERION PHARMACEUTICALS

Presentation

LOJUXTA 5 mg, hard capsule B/28 (CIP: 34009 276 259 9 2) LOJUXTA 10 mg, hard capsule B/28 (CIP: 34009 276 260 7 4) LOJUXTA 20 mg, hard capsule B/28 (CIP: 34009 276 261 3 5)

Posted on May 30 2014